ClinicalTrials.gg

Program

tifeglipron

Also written as “RO7795081”, “Tifeglipron” and “CT-996”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by Hoffmann-La Roche.

Furthest: phase 2, since Jul 22, 20256 company-led studies, 4 open or runningNext primary completion: Dec 7, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche64 open or runningphase 2since Jul 22, 2025Feb 23, 2023Dec 7, 2026phase 1 · NCT06982131
  • Named in Hoffmann-La Roche’s own pipeline as RG6652 tifeglipron, phase 2, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2023First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05814107 · 94 enrolled · Australia, Mexico
  2. May 13, 2025Phase 1 study in OverweightNCT06982131 · 40 enrolled · Netherlands
  3. Jul 22, 2025Phase 2 study in ObesityNCT07081958 · 352 enrolled · United States
  4. Aug 1, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07112872 · 330 planned · United States, Hungary, Poland and more
  5. Mar 23, 2026Phase 1 study in OverweightNCT07499050 · 30 enrolled · China
  6. Jul 29, 2026Phase 1 study in Renal InsufficiencyNCT07741604 · 60 planned · United States
  7. Oct 1, 2026Primary completion moved from 2026-11-27 to 2028-02-05Date moved laterphase 2 · +14 months · NCT07112872

Ahead

  1. Dec 7, 2026Primary completion: phase 1 study in OverweightNCT06982131
  2. Jan 9, 2027Primary completion: phase 1 study in OverweightNCT07499050
  3. Feb 1, 2028Primary completion: phase 1 study in Renal InsufficiencyNCT07741604
  4. Feb 5, 2028Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07112872

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07741604Renal Insufficiency · United States1RecruitingFeb 1, 202860
NCT07499050Overweight · China1Active, not recruitingJan 9, 202730
NCT07112872Diabetes Mellitus, Type 2 · United States, Hungary, Poland and more2RecruitingFeb 5, 2028330
NCT07081958Obesity · United States2CompletedApr 28, 2026352
NCT06982131Overweight · Netherlands1Active, not recruitingDec 7, 202640
NCT05814107Diabetes Mellitus, Type 2 · Australia, Mexico1CompletedNov 7, 202594

How it is read

Names in the registry

  • “RO7795081”, 3 entries
  • “Tifeglipron”, 2 entries
  • “CT-996”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.